Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has identified several potential candidates from its Respiratory Syncytial Virus (RSV) AI collaboration with One Three Biotech.
Dublin-based Poolbeg said it has prioritised compounds with existing Phase I clinical data and which could, if successfully validated, be repositioned as novel treatments for RSV infection.
These candidates are well positioned to enter clinical trials quickly to generate early human efficacy data for RSV, Poolbeg added.
RSV inflames the smallest airways of the lungs, is especially dangerous for children and dangerous for adults over the age of 65,
Public health officials have been warning this year already about the impact of a 'tripledemic' of SARS-CoV-2, influenza and RSV on healthcare systems, with hospitalisations of young children in the US with RSV at the highest level ever recorded, Poolbeg noted in its statement.